# Aprea Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Aprea Therapeutics, Inc.).

## Overview

Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on discovering and developing targeted small-molecule therapies for biomarker-defined cancers. The company’s core scientific approach is synthetic lethality, aiming to exploit cancer-specific genetic vulnerabilities to improve tumor killing while limiting harm to healthy tissue. Its pipeline has evolved from earlier mutant p53 programs toward DNA damage response, or DDR, pathway targets acquired and advanced after the Atrin transaction in 2022. Aprea remains pre-commercial and is funded primarily through equity financing and grants rather than product sales.

## Products & services

• ATRN-119, an ATR inhibitor for DDR-driven cancers
• APR-1051, a WEE1 inhibitor in oncology development
• APR-1602, a macrocyclic DYRK1A/B inhibitor
• Synthetic lethality-based cancer drug discovery
• Preclinical and IND-enabling development programs
• Combination-therapy research with PARP inhibitors and other agents

- **Clinical-stage oncology candidates** (0%) — Small-molecule drug candidates being advanced through preclinical, IND-enabling, and clinical development for biomarker-defined cancers.
- **DNA damage response inhibitors** (70%) — Programs targeting ATR, WEE1, and related DDR pathways intended to create synthetic lethality in tumor cells.
- **Early discovery pipeline** (20%) — Earlier-stage research assets, including undisclosed DDR targets and next-generation oncology molecules.
- **Research collaborations and grants** (10%) — Non-product funding and scientific support, including grant-backed combination studies and potential partnering.

- ATRN-119, an ATR inhibitor for DDR-driven cancers
- APR-1051, a WEE1 inhibitor in oncology development
- APR-1602, a macrocyclic DYRK1A/B inhibitor
- Synthetic lethality-based cancer drug discovery
- Preclinical and IND-enabling development programs
- Combination-therapy research with PARP inhibitors and other agents

## Customers

Aprea does not currently sell commercial products, so its near-term counterparties are primarily research funders, clinical investigators, and potential licensing or collaboration partners rather than end-market patients. The company’s eventual customers would be oncology physicians and hospitals treating biomarker-defined cancer patients if any candidate reaches approval. In the development phase, the company also relies on contract manufacturers, CROs, and academic or government research collaborators to advance its pipeline. Because the business is pre-revenue, partner interest in the science and clinical data is central to future monetization.

- **Future oncology treatment providers** (primary) — Cancer centers and oncologists would use approved therapies for patients whose tumors match the relevant genetic biomarkers.
- **Biomarker-defined cancer patients** (primary) — Patients with DDR-related or other genetically defined tumors are the intended end users of the company’s precision oncology drugs.
- **Pharmaceutical licensing partners** (secondary) — Larger biopharma companies may license or co-develop assets to gain access to Aprea’s synthetic lethality programs.
- **Research grant providers** (secondary) — Public funding bodies such as the National Cancer Institute support selected preclinical and combination studies.
- **Contract development and manufacturing partners** (secondary) — Specialist vendors provide API, drug product, and clinical supply services needed to advance candidates.

- Oncology patients with biomarker-defined cancers, if candidates are approved
- Hospitals and cancer centers that would prescribe targeted therapies
- Potential pharma partners seeking licensed DDR oncology assets
- Government and academic grant sponsors supporting research programs
- CROs and contract manufacturers that enable development and supply

## Geography

Aprea is headquartered in Doylestown, Pennsylvania, and reports in U.S. dollars, but it also operates through its Swedish subsidiary Aprea AB. The company’s historical roots are in Sweden, while its corporate structure and capital markets presence are now centered in the United States. Its development work is global in nature because oncology R&D depends on external CROs, contract manufacturers, and clinical sites rather than a large owned manufacturing footprint. Geography matters mainly through foreign-currency exposure, cross-border operations, and the location of scientific talent and development infrastructure.

- Headquartered in Doylestown, Pennsylvania, United States
- Operates through wholly owned Swedish subsidiary Aprea AB
- Reports consolidated results in U.S. dollars
- Foreign-currency exposure arises from Swedish operations and cash balances
- Development and manufacturing are outsourced rather than tied to one region
- Clinical and research activities can span multiple countries through partners

## Strategy

Aprea’s strategy is to advance a focused pipeline of synthetic lethality oncology assets that target DDR pathways and biomarker-defined tumors. The company is prioritizing ATRN-119 and APR-1051 while also keeping earlier-stage programs such as APR-1602 and an undisclosed DDR target moving toward IND-enabling work. Combination strategies, including pairing with PARP inhibitors and other agents, are important because they may broaden efficacy and strengthen the scientific rationale for clinical development. The company also seeks external funding and partnership opportunities to extend runway and reduce the capital burden of drug development.

- **Advance lead DDR oncology assets** (short-term) — The company’s value creation depends on generating clinical proof-of-concept for its most advanced synthetic lethality programs.
- **Expand combination-therapy opportunities** (medium-term) — Combination regimens may improve efficacy and differentiate the assets in competitive oncology markets.
- **Progress early-stage pipeline assets** (medium-term) — Earlier programs provide future pipeline depth and reduce dependence on a small number of candidates.
- **Secure non-dilutive and partner funding** (short-term) — As a clinical-stage biotech with no product revenue, external capital is essential to fund development and extend runway.

- Advance ATRN-119 and APR-1051 as the core DDR pipeline
- Use synthetic lethality to target genetically defined cancers
- Explore combination regimens to improve anti-tumor activity
- Move APR-1602 toward IND-enabling studies
- Develop and protect intellectual property around novel oncology mechanisms
- Seek grants and partnerships to support capital-intensive R&D

## Risks

Aprea faces the typical risks of a clinical-stage biotech: its programs may fail in preclinical or clinical testing, and even promising science may not translate into approvable or commercially viable drugs. The company has incurred significant losses since inception and expects to continue losing money, so its ability to fund operations depends on future capital raises, grants, or partnerships. Because it has no product sales, any delay in development or financing can quickly pressure liquidity and increase dilution risk. Additional risks include Nasdaq continued listing compliance, dependence on third-party manufacturers and regulators, and foreign-currency exposure from its Swedish subsidiary.

- **Need for additional capital** [high] — The company has incurred significant losses and has no commercial product revenue, so it must raise funds to continue development.
- **Clinical development failure** [high] — Drug candidates may not demonstrate sufficient safety, efficacy, or biomarker-driven benefit to advance.
- **Nasdaq continued listing compliance** [high] — Failure to meet listing requirements could lead to delisting and reduce liquidity and financing flexibility.
- **Manufacturing and supply-chain dependence** [medium] — The company relies on contract manufacturers for APIs and drug product, which can create quality, capacity, and timing risks.
- **Foreign exchange volatility** [low] — Operations through Aprea AB create translation and remeasurement effects in consolidated U.S. dollar reporting.

- Clinical and preclinical programs may fail to show safety or efficacy
- The company has no product revenue and depends on external financing
- Future equity raises could dilute existing shareholders
- Nasdaq listing compliance risk could affect trading liquidity
- Third-party manufacturing and CRO dependence can delay development
- Regulatory approval risk is high in oncology drug development
- Foreign-currency movements can affect reported results through Aprea AB

## Accounting

Aprea’s accounting is dominated by development-stage biotech judgments rather than revenue recognition. The company has not generated product sales, so reported results are driven mainly by research and development expense, accrued R&D estimates, and general and administrative costs. Because it uses contract manufacturers and CROs, management must estimate accrued research and development expenses for work performed but not yet invoiced, which can move quarterly results. The company also records foreign-currency translation effects from its Swedish subsidiary, and it maintains a full valuation allowance against deferred tax assets because realization is considered unlikely at this stage.

- **Accrued research and development expenses** — Can materially affect quarterly R&D expense and net loss
- **Foreign currency translation and remeasurement** — Affects other comprehensive loss and reported earnings volatility
- **Valuation allowance on deferred tax assets** — Prevents recognition of tax benefits that would otherwise reduce losses
- **Grant revenue recognition** — Can cause period-to-period volatility in other income

- Accrued research and development expenses affect quarterly operating loss
- No product revenue means results are driven by R&D and G&A spending
- Foreign-currency remeasurement and translation affect other income/loss
- Valuation allowance reflects uncertainty over future tax asset realization
- Grant revenue, if any, may be episodic and tied to specific research milestones
- Outsourced development creates judgment around vendor accrual timing

---

*Last updated: 2026-08-11T04:46:21.147605+00:00*